Moslehi J - Search Results

1

In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers.

Cai C, Fang J, Guo P, Wang Q, Hong H, Moslehi J, Cheng F. Cai C, et al. Among authors: moslehi j. J Chem Inf Model. 2018 May 29;58(5):943-956. doi: 10.1021/acs.jcim.7b00641. Epub 2018 May 10. J Chem Inf Model. 2018. PMID: 29712429 Free PMC article.

2

Cancer-drug discovery and cardiovascular surveillance.

Groarke JD, Cheng S, Moslehi J. Groarke JD, et al. Among authors: moslehi j. N Engl J Med. 2013 Nov 7;369(19):1779-81. doi: 10.1056/NEJMp1313140. Epub 2013 Nov 1. N Engl J Med. 2013. PMID: 24180496 No abstract available.

3

Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.

Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJ. Bellinger AM, et al. Among authors: moslehi jj. Circulation. 2015 Dec 8;132(23):2248-58. doi: 10.1161/CIRCULATIONAHA.115.010484. Circulation. 2015. PMID: 26644247 Free PMC article. Review.

4

Cardiovascular Complications of Novel Multiple Myeloma Treatments.

Li W, Cornell RF, Lenihan D, Slosky D, Jagasia M, Piazza G, Moslehi J. Li W, et al. Among authors: moslehi j. Circulation. 2016 Mar 1;133(9):908-12. doi: 10.1161/CIRCULATIONAHA.115.018351. Circulation. 2016. PMID: 26927008 Review. No abstract available.

5

Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.

Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, Richardson PG, Moslehi J. Li W, et al. Among authors: moslehi j. JAMA Oncol. 2017 Jul 1;3(7):980-988. doi: 10.1001/jamaoncol.2016.3350. JAMA Oncol. 2017. PMID: 27632640 Review.

6

Cardiovascular Toxic Effects of Targeted Cancer Therapies.

Moslehi JJ. Moslehi JJ. N Engl J Med. 2016 Oct 13;375(15):1457-1467. doi: 10.1056/NEJMra1100265. N Engl J Med. 2016. PMID: 27732808 Review. No abstract available.

7

Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.

Sethi TK, Basdag B, Bhatia N, Moslehi J, Reddy NM. Sethi TK, et al. Among authors: moslehi j. Curr Hematol Malig Rep. 2017 Jun;12(3):257-267. doi: 10.1007/s11899-017-0369-y. Curr Hematol Malig Rep. 2017. PMID: 28233150 Review.

8

Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it?

Stack JP, Moslehi J, Sayed N, Wu JC. Stack JP, et al. Among authors: moslehi j. Eur Heart J. 2019 Jun 7;40(22):1764-1770. doi: 10.1093/eurheartj/ehx811. Eur Heart J. 2019. PMID: 29377985 Free PMC article. Review.

9

Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms.

Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE. Alexandre J, et al. Among authors: moslehi jj. Pharmacol Ther. 2018 Sep;189:89-103. doi: 10.1016/j.pharmthera.2018.04.009. Epub 2018 Apr 24. Pharmacol Ther. 2018. PMID: 29698683 Review.

10

Immune checkpoint inhibitors and cardiovascular toxicity.

Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Lyon AR, et al. Among authors: moslehi j. Lancet Oncol. 2018 Sep;19(9):e447-e458. doi: 10.1016/S1470-2045(18)30457-1. Lancet Oncol. 2018. PMID: 30191849 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

277 results

Search Page

Filters